01 Integration of Robotic Assistance in Prostate Procedures The benign prostatic hyperplasia treatment devices market analysis shows increasing integration of robotic assistance and computer-guided technologies in prostate procedures. These technologies help urologists control instrument movements, improve procedural visualization, and perform precise tissue removal or ablation.
02 Development of Devices Designed to Preserve Sexual Function BPH treatment devices are being designed to relieve urinary symptoms while preserving sexual function, particularly ejaculatory function. Technologies such as prostatic urethral lift and selected minimally invasive thermal therapies aim to reduce obstruction, while limiting damage to surrounding tissues.
01 Supply chain disruptions are expected to have a high impact on the BPH treatment devices market share due to dependence on precision-engineered components, medical-grade polymers, laser systems, and electronic control units. The market is expected to follow a stair-step recovery, as shortages of specialized components, manufacturing delays, and sterilization constraints can affect device production and deliveries before supply networks stabilize. The market is expected to grow at a CAGR of 9.14%, but supply chain constraints could lower this by 1.0 percentage point, resulting in a growth of around 8.14%. As supply conditions normalize, the BPH treatment devices market growth is expected to gradually return to 9.14%.
01 The BPH treatment devices market forecasts strategic investment activity driven by the commercialization of minimally invasive prostate treatment devices and advancements in reversible implant technologies.
02 Key Investment and Funding Activities in Benign Prostatic Hyperplasia Treatment Devices Market, 2026 Company Value (USD) Details Zenflow USD 52 million In October 2026, Zenflow closed an oversubscribed Series D financing round led by Cook Medical, with participation from ClavystBio and existing investors. The funding will accelerate commercialization of its Zenflow Spring System, a minimally invasive and reversible device for treating benign prostatic hyperplasia (BPH). Rivermark Medical USD 20 million In May 2026, Rivermark Medical raised Series D financing led by Andera Partners to support its RAPID III pivotal clinical trial, pursue U.S. regulatory approval, and prepare for commercialization of the FloStent System, a reversible device-based BPH treatment.
01 Demand for Laser-Based BPH Treatments and Minimally Invasive BPH Treatment Procedures Drives Market Demand for laser-based treatments is supporting the adoption of devices used to manage benign prostatic hyperplasia (BPH). Procedures such as holmium laser enucleation of the prostate (HoLEP) use specialized equipment to remove excess prostate tissue and relieve urinary symptoms. The need for effective treatment options for enlarged prostate conditions is contributing to BPH treatment devices market growth.Preference for minimally invasive procedures is encouraging the use of devices that treat BPH while reducing surgical trauma and recovery time. Technologies such as prostatic urethral lift and water vapor thermal therapy offer alternatives to conventional surgery for suitable patients. The demand for less invasive treatment options is supporting the adoption of BPH treatment devices.
01 High Cost of Advanced BPH Treatment Devices and Risk of Postoperative Complications Restrain Market Expansion Advanced benign prostatic hyperplasia (BPH) treatment devices, including laser systems, water vapor therapy equipment, and prostatic urethral lift systems, require substantial investment in specialized technology and supporting instruments. Additional expenses related to installation, maintenance, and physician training increase the overall cost of adoption. BPH treatment procedures using specialized devices may cause postoperative complications, including urinary tract infections, bleeding, temporary urinary retention, and urethral irritation. These risks can influence patient treatment preferences and require follow-up care, increasing the overall burden on healthcare providers.
01 Expansion of Office-Based BPH Treatment Solutions and Devices for Patients with Complex Prostate Conditions Offers Growth Opportunities Medical device manufacturers can target urology clinics and outpatient centers seeking treatment options that can be performed without a traditional hospital-based surgical setting. Revenue opportunities include device sales, disposable procedure components, equipment leasing, and training services for urology practices, contributing to benign prostatic hyperplasia treatment devices market growth.Device developers can target urologists treating patients whose prostate size, urinary symptoms, or existing health conditions influence treatment selection. Companies can generate revenue through specialized device portfolios, procedure kits, clinical training programs, and supply agreements with urology centers.
October 2026 Prodeon Medical began controlled U.S. commercial use of its Urocross Expander System after the first commercial procedure.
September 2026 Boston Scientific received FDA 510(k) clearance for a change to its Rezūm System, a water-vapor therapy device used to treat benign prostatic hyperplasia (BPH).